Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...

Padcev plus Keytruda shows superior response and survival rates in first-line metastatic urothelial carcinoma treatment compared to chemotherapy. Padcev monotherapy provides clinical benefits in later ...

How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on ...

BMS is already testing the combo against just Keytruda as a first-line treatment in a Phase III trial in KRAS G12C-mutant and ...

FDA approved Keytruda with Herceptin and chemotherapy for HER2-positive gastric/GEJ adenocarcinoma with PD-L1 expression. KEYNOTE-811 study showed improved progression-free and overall survival with ...